Neos Therapeutics (NEOS) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Neos Therapeutics (NEOS) Prepping for Adzenys Commercialization - UBS
March 18, 2016 8:59 AM EDTUBS analyst, Marc Goodman highlighted 5 key takeaways from a management call with Neos Therapeutics (NASDAQ: NEOS) :
1) On Adzenys XR-ODT, the launch is on track for 2Q16 as previously stated, with 80% of the 125 planned sales reps having been hired. Mgt expects a slow initial ramp starting in 2Q but expects Rxs to pick up in AugOct with the back-to-school season, which is in line with our expectations. For pricing, mgt is looking at $200-300 gross/month in line with branded and generic competition.... More
